<DOC>
	<DOCNO>NCT02278068</DOCNO>
	<brief_summary>The purpose research study collect information new treatment Type 2 Diabetes Mellitus ( T2DM ) , use medical device call Metabolic Neuromodulation System intend help regulate blood glucose level patient whose ( T2DM ) well control despite treatment multiple medication . The medical device delivers low-level radiofrequency energy wall blood vessel liver disrupt nerve lead liver . Previous research show disrupting nerve may lead lower blood sugar level .</brief_summary>
	<brief_title>COMPLEMENT Study- A First Human Study Metabolic Neuromodulation Therapy</brief_title>
	<detailed_description>Prospective , First-in-Human ( FIH ) , multi-center , non-randomized trial evaluate initial safety performance hepatic sympathetic denervation aid glycemic control .</detailed_description>
	<mesh_term>Metabolic Diseases</mesh_term>
	<criteria>Age 1865 year Uncontrolled T2DM , evidence HbA1c level , consistent oral antihyperglycemic drug regimen least two different drug class Documented status stable lifestyle modification Diagnosed type 1 diabetes mellitus History diagnosis proliferative retinopathy advance autonomic neuropathy Estimated glomerular filtration rate ( GFR ) &lt; 60mL/min/1.73m2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Type 2 diabetes</keyword>
</DOC>